<DOC>
	<DOCNO>NCT02056210</DOCNO>
	<brief_summary>The objective study ass whether difference mobilization CD34+ cell EPC response Mozobil patient diabetes mellitus compare subject without diabetes . Currently , non-invasive method study bone marrow function human . This project aim evaluate patient type 1 type 2 diabetes mellitus ability mobilize CD34+ cell EPC bone marrow periphery response exogenous mobilize agent AMD3100 / plerixafor ( Mozobil ) , compare group non-diabetic individual . While recently show diabetic patient respond mobilization induce G-CSF ( Filgrastim ) , investigator herein hypothesize diabetic patient adequately respond mobilization induce Plerixafor</brief_summary>
	<brief_title>Stem Cell Mobilization With Plerixafor Diabetic v Control Subjects</brief_title>
	<detailed_description>Scientific background . Diabetes mellitus associate increased prevalence incidence cardiovascular disease . It believe high cardiovascular risk diabetes attributable adverse effect glucotoxicity lipotoxicity endothelial cell . Recent data indicate endothelial repair mechanism play important role determine integrity endothelium thus global health cardiovascular system . Data research group demonstrate cell involve endothelial regeneration neo-angiogenesis ( include CD34+ cell endothelial progenitor cell , EPC ) reduce number dysfunctional patient diabetes mellitus . EPC belong CD34+ cell population define base co-expression endothelial-lineage marker , VEGF receptor 2 ( VEGFR2 KDR ) . These cell impair diabetic patient cardiovascular disease . It believe change represent one cause cardiovascular damage diabetes . The mechanisms underlying decrease EPC progenitor cell diabetes fully understood . Normally , EPC reside bone marrow circulating level peripheral blood low . In response ischemic injury vascular damage , EPC mobilize bone marrow peripheral blood . Data obtain experimental model diabetes mellitus indicate defect EPC mobilization bone marrow peripheral circulation response ischemia , result impairment post-ischemic neo-angiogenetic process . Similar experimental result obtain different research group . Our data also show experimental diabetes reduces marrow response exogenous mobilize agent G-CSF SCF . Other clinical data human research group confirm hypothesis defect bone marrow patient diabetes mellitus . In particular , diabetes cause profound alteration bone marrow microenvironment associate microangiopathy alteration stem cell niche . These result confirm study mouse model type 1 diabetes , first time identify specific form microangiopathy cause depletion CD34+ cell EPC bone marrow . As consequence bone marrow damage , research group recently show mobilization CD34+ cell EPC phenotype profoundly defective patient type 1 2 diabetes mellitus . To reach conclusion , investigator use test bone marrow reserve administer low dose human recombinant G-CSF ( Filgrastim ) . The study show sub-maximal marrow stimulation able highlight difference diabetic non-diabetics absolutely safe , since significant side effect . In hematology context , also previously show diabetes factor predictive `` poor mobilization '' expose patient increase risk fail stem cell collection autologous stem cell transplantation . From functional/mechanistic standpoint , demonstrate impairment CXCL12/CXCR4 axis probably contribute lack mobilization bone marrow stem/progenitor cell associate diabetes . The drug AMD3100 / plerixafor ( Mozobil Â® ) direct antagonist CXCR4 inhibits cellular signal keep stem / progenitor cell within bone marrow . For reason , AMD3100 / Plerixafor rapidly effective mobilization bone marrow stem cell . From experimental point view , observe diabetic animal , although responsive mobilization induce ischemia G-CSF , responsive mobilization induce AMD3100 / Plerixafor . Mozobil currently approve Italy stem cell mobilization patient multiple myeloma lymphoma purpose auto-transplantation , combination G-CSF , poorly mobilize patient ( see SmPC ) . At stage , effectiveness Mozobil induce mobilization stem / progenitor cell diabetic patient yet test . Scientific question . The objective study ass whether difference mobilization CD34+ cell EPC response Mozobil patient diabetes mellitus compare subject without diabetes . Currently , non-invasive method study bone marrow function human . This project aim evaluate patient type 1 type 2 diabetes mellitus ability mobilize CD34+ cell EPC bone marrow periphery response exogenous mobilize agent AMD3100 / plerixafor ( Mozobil ) , compare group non-diabetic individual . While recently show diabetic patient respond mobilization induce G-CSF ( Filgrastim ) , investigator herein hypothesize diabetic patient adequately respond mobilization induce Plerixafor . Plausibility clinical relevance . It believe alteration stem/progenitor cell secondary bone marrow defect contribute development clinical diabetic microangiopathy macroangiopathy . For reason , great interest explore mechanisms cause progenitor cell defect diabetes possible strategy cope . A wealth data come animal , human epidemiologic study indicate mobilize response G-CSF impair diabetic patient . Therefore , stem mobilization diabetes consider `` unmet clinical need '' . On side , preclinical experimental data animal model diabetes indicate AMD3100 / Plerixafor able mobilize stem progenitor cell . The clinical relevance project lie possibility identify treatment able restore stem/progenitor cell mobilization diabetes . This favorable implication chronic diabetic complication , microangiopathy cardiovascular disease . In fact , project relevant pathophysiological point view , since believe EPC protect vascular complication diabetes . Furthermore , hematologic standpoint , aware diabetic patient hyporesponsive G-CSF whilst respond adequately Plerixafor would allow individualize mobilization protocol view autologous hematopoietic stem cell transplantation . Expected adverse event . Treatment Mozobil combination G-CSF may associate mild adverse event ( see SmPC ) . Compared placebo + G-CSF , use Mozobil + G-CSF patient two clinical trial induce significantly high number grade 1-2 adverse reaction : diarrhea ( 37 % vs 17 % ) , nausea ( 34 % vs 22 % ) , flatulence ( 7 % vs 3 % ) , injection site reaction ( 34 % vs 10 % ) , dizziness ( 11 % vs 6 % ) . No side effect grade 3-4 report . In present study Mozobil give monotherapy , ie combination G-CSF . Based literature data , adverse event may expect type treatment mild : - In study 20 healthy volunteer grade 1 side effect report response monotherapy treatment Mozobil sc : cramp bloat , flatulence , dry mouth . - In study involve 10 healthy volunteer treat Mozobil sc monotherapy follow mild side effect observe ( grade 1 ) : erythema itch site injection , headache , perioral paresthesia , nausea , abdominal swelling . - A study involve 25 healthy donor treat Mozobil sc monotherapy report following adverse event grade 1 ( mild ) : dizziness , nausea , flatulence , discomfort feeling warmth injection site , perioral paresthesia , sweat , cephalea . On basis data , assume use Mozobil monotherapy safe expect side effect mild tolerable patient . In addition , almost drug , Mozobil induce allergic reaction anaphylaxis .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Inclusion criterion : Diabetes mellitus ( type 1 2 ) ( patient ) absence diabetes mellitus carbohydrate metabolism alteration ( non diabetic control ) Age 2065 year ; Both gender ; Informed consent . Exclusion criterion : Age &lt; 20 &gt; 65 year ; Pregnancy lactation * Recent surgery trauma ; Recent acute disease ( within 2 month study entry ) ; Immune diseases ( except type I diabetes autoimmune thyroiditis ) ; Chronic infectious disease ; Hematologic malignancies either past present ; Solid tumor know strongly suspect ; Leukocytosis , leukopenia , thrombocytopenia ; Solid organ transplant immunosuppression ; Alteration hepatic function ( transaminases &gt; 2 ULN ) ; Severe chronic diabetic micro macroangiopathy HbA1c &gt; 11 % . Deficit renal function ( eGFR &lt; 50 ml/m2 ) ; Significant abnormalities peripheral lymphocyte immunophenotype ; Known hypersensitivity Mozobil excipients ; Refusal / inability provide inform consent . woman childbearing potential participate trial use effective oral contraception ; negative pregnancy test require study entry ) . Women ask continue oral contraception 3 month Mozobil administration . All antidiabetic medication allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Stem cell</keyword>
	<keyword>Bone marrow</keyword>
</DOC>